Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 juin 2020 02h30 HE | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise

Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
10 mars 2020 16h12 HE | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results

Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...
06 mars 2020 13h00 HE | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results

CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
10 déc. 2018 16h49 HE | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPCSingle-arm CPI-1205 / abiraterone / prednisone combination added to...